⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HELP News
Cybin Inc. Common Stock
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
prnewswire.com
HELP
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
prnewswire.com
GHRS
HELP
DFTX
JNJ
CMPS
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
prnewswire.com
HELP
ATAI
JNJ
CMPS
LLY
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
globenewswire.com
HELP
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
prnewswire.com
GHRS
HELP
DFTX
ATAI
CMPS
LLY
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
globenewswire.com
HELP
DFTX
CMPS
GHRS
JNJ
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
globenewswire.com
HELP
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
prnewswire.com
GHRS
HELP
DFTX
CMPS
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
globenewswire.com
HELP
Helus Pharma™ Announces US$50 Million Underwritten Offering
globenewswire.com
HELP